Platinum
- Generic Name
- Platinum
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- Pt
- CAS Number
- 7440-06-4
- Unique Ingredient Identifier
- 49DFR088MY
- Background
Platinum is under investigation for the treatment of Metastatic Breast Cancer, Non-small Cell Lung Cancer, Gastric Large Cell Neuroendocrine Carcinoma, Colorectal Large Cell Neuroendocrine Carcinoma, and Pancreatic Large Cell Neuroendocrine Carcinoma, among others. Platinum has been investigated for the treatment and supportive care of Ovarian Cancer, Fallop...
- Associated Conditions
- -
- Associated Therapies
- -
Zolbetuximab Plus Chemotherapy Wins EU Approval for Advanced CLDN18.2+ Gastric/GEJ Cancer
The European Commission approved zolbetuximab (Vyloy) plus chemotherapy for HER2-negative, Claudin 18.2-positive gastric and gastroesophageal junction cancers. Zolbetuximab, targeting CLDN18.2, showed improved progression-free and overall survival in phase 3 trials SPOTLIGHT and GLOW. Common side effects included vomiting, nausea, and decreased appetite.
Related Clinical Trials:
Merck/Daiichi Sankyo's ADC candidate shows promise in phase 3 lung cancer trial
Merck & Co and Daiichi Sankyo's late-stage trial of patritumab deruxtecan in EGFR-mutated NSCLC met primary endpoint of PFS, showing significant improvement over standard chemotherapy. The trial continues to assess overall survival, with plans to discuss findings with regulatory authorities.
Patritumab Deruxtecan Demonstrates Significant Survival Improvement in Locally Advanced
Patritumab deruxtecan showed significant PFS improvement in EGFR-mutated NSCLC patients post-TKI treatment, outperforming standard platinum-based doublet chemotherapy in the HERTHENA-Lung02 trial. Daiichi Sankyo and Merck plan to discuss these findings with regulatory authorities.
ADC improves survival in NSCLC trial
Daiichi Sankyo and MSD report Phase III HERTHENA-Lung02 trial of patritumab deruxtecan met primary endpoint of progression-free survival in EGFR-mutated NSCLC patients. The trial showed a significant PFS improvement for patritumab deruxtecan versus chemotherapy, with a safety profile consistent with previous studies.
Merck, Daiichi Score Late-Stage NSCLC Win for ADC, Flag Two Deaths
Merck and Daiichi Sankyo's patritumab deruxtecan met primary endpoint in Phase III HERTHENA-Lung02 study for EGFR-mutated non-small cell lung cancer, showing significant improvement in progression-free survival. Safety profile consistent with prior studies, though two grade 5 interstitial lung disease deaths occurred. Full results to be presented at a medical meeting.
Patritumab Deruxtecan Demonstrated Statistically Significant Improvement in Progression-Free Survival Versus Doublet Chemotherapy in Patients with Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer in HERTHENA-Lung02 Phase 3 Trial
Patritumab deruxtecan showed significant PFS improvement in HERTHENA-Lung02 trial for EGFR-mutated NSCLC patients previously treated with EGFR TKI, compared to platinum plus pemetrexed chemotherapy.
Merck's KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy (CRT) Reduced Risk of ...
KEYNOTE-A18, a Phase 3 trial, showed KEYTRUDA (pembrolizumab) plus concurrent chemoradiotherapy (CRT) improved overall survival (OS) in high-risk locally advanced cervical cancer patients, reducing the risk of death by 33% compared to CRT alone. The results were presented at the ESMO Congress 2024 and published in The Lancet.
HUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2024 and the ...
HUTCHMED announces new data from studies of compounds to be presented at 2024 WCLC and ESMO Congresses. Key findings include positive results from the FLOWERS study, showing deeper and more durable response with osimertinib plus savolitinib in EGFRm, MET-aberrant advanced NSCLC patients compared to osimertinib monotherapy.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath